Vincent H H, Man In't Veld A J, Boomsma F, Wenting G J, Schalekamp M A
Br J Clin Pharmacol. 1982 May;13(5):717-21. doi: 10.1111/j.1365-2125.1982.tb01442.x.
Dose-dependent increments of plasma noradrenaline were observed during graded infusions of (±)isoprenaline (3.5-35 ng kg min i.v.) in seven normal subjects and in ten subjects with borderline hypertension. At the highest dose of isoprenaline, noradrenaline rose by 166 ± 16 pg/ml in normals and by 169 ± 34 pg/ml in hypertensives (mean ± s.e. mean). In the subjects with borderline hypertension isoprenaline infusions were repeated after 7 days of treatment with (±)propranolol (320 mg/day, divided into 4 doses) and subsequently after 7 days of treatment with (±)atenolol (100 mg/day) 2-3 h after the morning dose of β-adrenoceptor blocker. The dose-response curve for plasma noradrenaline was shifted to higher doses of isoprenaline by a factor of 4 by atenolol and the heart rate response was similarly shifted. The heart rate response was shifted by a factor of 16 by propranolol, but plasma noradrenaline did not change after isoprenaline under propranolol treatment, even when isoprenaline was given at doses high enough to induce increments of heart rate similar to those without β-adrenoceptor blocker treatment. In the subjects with borderline hypertension mean and diastolic intra-arterial pressures fell at the highest dose of isoprenaline by 9 ± 2 and 13 ± 2 mm Hg respectively. These effects were antagonized by propranolol and not by atenolol. The observed rise in plasma noradrenaline after isoprenaline might have been caused by baro-reflex-stimulation of central sympathetic outflow. The isoprenaline-induced decrease in mean arterial pressure, however, was small. Moreover pulse pressure rose and this tends to suppress rather than stimulate baroreflex-mediated sympathetic activity. Activation of presynaptic β-adrenoceptors, allegedly of the β-subtype, is known to facilitate noradrenaline release upon nerve stimulation of isolated tissues. Our results lend support to the hypothesis that such a facilitatory mechanism is also operative in intact man.
在7名正常受试者和10名临界高血压受试者中,静脉输注不同剂量(±)异丙肾上腺素(3.5 - 35 ng·kg⁻¹·min⁻¹)时,观察到血浆去甲肾上腺素呈剂量依赖性增加。在异丙肾上腺素的最高剂量时,正常受试者的去甲肾上腺素升高166±16 pg/ml,高血压受试者升高169±34 pg/ml(均值±标准误均值)。在临界高血压受试者中,先用(±)普萘洛尔(320 mg/天,分4次给药)治疗7天,然后在早晨服用β-肾上腺素能受体阻滞剂2 - 3小时后,再用(±)阿替洛尔(100 mg/天)治疗7天,之后重复输注异丙肾上腺素。阿替洛尔使血浆去甲肾上腺素的剂量 - 反应曲线向更高剂量的异丙肾上腺素方向移动了4倍,心率反应也有类似的移动。普萘洛尔使心率反应移动了16倍,但在普萘洛尔治疗下,即使给予足够高剂量的异丙肾上腺素以诱导与无β-肾上腺素能受体阻滞剂治疗时相似的心率增加,血浆去甲肾上腺素在输注异丙肾上腺素后也没有变化。在临界高血压受试者中,异丙肾上腺素的最高剂量使平均动脉压和舒张压分别下降9±2和13±2 mmHg。这些效应被普萘洛尔拮抗,而阿替洛尔无此作用。异丙肾上腺素后观察到的血浆去甲肾上腺素升高可能是由压力反射刺激中枢交感神经传出引起的。然而,异丙肾上腺素引起的平均动脉压下降幅度较小。此外,脉压升高,这倾向于抑制而非刺激压力反射介导的交感神经活动。据称,突触前β-肾上腺素能受体(β亚型)的激活在离体组织的神经刺激时可促进去甲肾上腺素释放。我们的结果支持这样一种假说,即这种促进机制在完整人体中也起作用。